Skip to main content

αMT Facts

Psychedelic; Stimulant; Substituted tryptamine; Serotonin 2A receptor agonist

Description

αMT (alpha-methyltryptamine) — street name Spirals — is a synthetic psychedelic-stimulant of the tryptamine class. It releases serotonin, dopamine, and norepinephrine while activating serotonin receptors, producing a combined psychedelic-stimulant experience.[1][2]

Subjective effects include geometric visual patterns, color enhancement, thought acceleration, euphoria, wakefulness, and emotional warmth. The experience layers psychedelic perception over a stimulant-empathogenic baseline — more physically activating and emotionally open than classical tryptamines, with an unusually long duration.

αMT does not produce physical dependence, and close analogs show low reinforcement potential.[3] The primary risk is serotonin overload: αMT inhibits the enzyme that clears serotonin while simultaneously flooding the brain with it, creating dangerous accumulation even without other drugs.[4][5]

Dose and durationby route · individual sensitivity varies

Oral(mg)
Threshold< 5 mgLight10 – 25 mgCommon25 – 40 mgStrong40 – 60 mgHeavy60+ mg

Starts in 60 – 180 minLasts 13 – 15 hoursAfter-effects 1 – 5 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Low
Physical dependence
None
Psychological dependence
Low
Withdrawal
None recorded
Compulsive redosing
Low

Tolerance

Builds
Rapid
Fully resets after
30 days
Carries over to
psilocybin; LSD; DMT; mescaline

Effectslikely at a common dose

Perception
none likely · 29 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise
Body
Wakefulness; Stimulation; Pupil dilation; +25 possible, including Temperature dysregulation, Nausea, Insomnia
Thinking
none likely · 30 possible, including Memory suppression, Cognitive impairment, Decision impairment
Feeling
none likely · 12 possible, including Anxiety, Emotional lability, Anhedonia
Self
none likely · 10 possible, including Derealization, Craving, Depersonalization
Time
none likely · 3 possible, including Temporal disorientation

Who shouldn't take it

Absolute
Psychotic disorders; Bipolar disorder; Pregnancy and breastfeeding; Concurrent serotonergic medication
Relative
Hypertension; Cardiac arrhythmia; Epilepsy; Hepatic impairment

Combinations65 recorded

Lethal (11)
Amphetamines; Cocaine; Dextromethorphan; MDMA, Amphetamines; MDMA, MDA; Methoxetamine; PCP; Psychedelics; Rolicyclidine; SNRIs; Stimulants
Dangerous (29)
5-HTP, Tryptophan; Alpha-2 adrenergic receptor antagonist; Buspirone; Ephedrine, Pseudoephedrine; Lithium; Local anesthetics; NRIs; Opioids; SSRIs; Antihistamines; Antipsychotics; Benzodiazepines, Barbiturates; Caffeine; Cannabis; Clonidine, Guanfacine; Dopamine agonists; DXM; GHB, Baclofen; GHB, GBL; Ibogaine; Ketamine, DXM, PCP; L-Tyrosine; Naltrexone; NDRIs (Wellbutrin); and 5 more, see full page
Caution (21)
See full page: psychedex.org/substances/amt
Not graded (4)
Not listed never means safe.

Seek help immediately if

Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:

  • Very high body temperature; hot, dry skin
  • Seizures
  • Chest pain; fast or irregular heartbeat
  • Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
  • Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
  • Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm

What to do

  1. Stay calm and reassure — remind them they took a drug and the effect will pass
  2. Move to a calm, quiet, safe space with low light; reduce noise and sensory input
  3. Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
  4. Talk them down gently; don't grab or restrain unless they're in danger
  5. For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
  6. If overheating, cool the body; be ready to give rescue breaths / CPR

The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P (2025) A systematic study of changes in monoamine neurotransmitters in the rat brain following acute administration of alpha-methyltryptamine (AMT), 5-methoxy-alpha-methyltryptamine (5-MeO-AMT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT). — Neuroscience research doi:10.1016/j.neures.2025.04.006
  2. [2]
    ^Li K, Li N, Chen Y, Li X, Qiao Y, Wang D, Di B, Xu P (2025) Effects of three tryptamines: alpha-methyltryptamine, 5-methoxy-alpha-methyltryptamine, and 5-methoxy-N,N-diisopropyltryptamine on acute toxicity, locomotor activity, and hallucinogenic behavior in mice. — Behavioural pharmacology doi:10.1097/fbp.0000000000000841
  3. [3]
    ^Abiero A, Botanas CJ, Sayson LV, Custodio RJ, de la Pena JB, Kim M, Lee HJ, Seo JW, Ryu IS, Chang CM, Yang JS, Lee YS, Jang CG, Kim HJ, Cheong JH (2019) 5-Methoxy-alpha-methyltryptamine (5-MeO-AMT), a tryptamine derivative, induces head-twitch responses in mice through the activation of serotonin receptor 2a in the prefrontal cortex. — Behavioural brain research doi:10.1016/j.bbr.2018.07.020
  4. [4]
    ^Wagmann L, Brandt SD, Kavanagh PV, Maurer HH, Meyer MR (2017) In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. — Toxicology letters doi:10.1016/j.toxlet.2017.03.007
  5. [5]
    ^Schifano F, Chiappini S, Miuli A, Corkery JM, Scherbaum N, Napoletano F, Arillotta D, Zangani C, Catalani V, Vento A, Pettorruso M, Martinotti G, Massimo DG, Guirguis A (2021) New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. — Experimental neurology doi:10.1016/j.expneurol.2021.113638
Print version
Report an issue